Physician profile
Allison J Smith
NPI 1528030871
$12,907.86
in general payments reported to CMS, 2019-2025
30 companies · $2,479 in 2025
The $2,479 reported for 2025 was more than what 90% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,234 · 2020: $1,170 · 2021: $2,302 · 2022: $2,023 · 2023: $1,508 · 2024: $1,192 · 2025: $2,479.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,178.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $2,747.89 | 2019-2023 | Tecnis Iol |
| Allergan, INC. | $1,947.93 | 2019-2022 | |
| Alcon Vision LLC | $1,323.15 | 2019-2025 | Clareon, Rocklatan, Argos |
| Harrow Eye, LLC | $1,216.74 | 2024-2025 | Vevye, Triesence |
| Abbvie INC. | $1,190.80 | 2022-2025 | Durysta, Lumigan, Alphagan P |
| Novartis Pharmaceuticals Corporation | $669.59 | 2019-2023 | |
| Tarsus Pharmaceuticals, INC. | $663.56 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $530.66 | 2019-2025 | Cequa |
| Bausch & Lomb Americas INC. | $413.50 | 2022-2025 | Xiidra, Miebo, Vyzulta |
| Oyster Point Pharma, INC. | $393.90 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Rxsight INC | $268.19 | 2025 | Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens, Light Adjustable Lens (Lal) |
| Sight Sciences, INC. | $230.44 | 2019-2022 | |
| Kala Pharmaceuticals, INC. | $168.17 | 2019-2021 | |
| Dompe US, INC. | $125.00 | 2021 | |
| Genentech USA, INC. | $121.82 | 2023 | Vabysmo |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $119.80 | 2023-2025 | Iyuzeh |
| Aerie Pharmaceuticals, INC. | $119.73 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $115.06 | 2019-2021 | |
| New World Medical,INC. | $110.70 | 2023 | |
| Glaukos Corporation | $92.65 | 2020-2023 | |
| Shire North American Group INC | $89.14 | 2019 | |
| Ivantis, INC | $63.87 | 2020 | |
| Dermira, INC. | $42.00 | 2020-2021 | |
| Ocular Therapeutix, INC. | $27.27 | 2022-2024 | Dextenza |
| Mallinckrodt Enterprises LLC | $25.44 | 2019 | |
| Novo Nordisk INC | $19.67 | 2021 | |
| Alcon Research LLC | $19.64 | 2019 | |
| Biotissue Holdings INC. | $17.83 | 2023 | |
| Boston Scientific Corporation | $17.65 | 2024 | Watchman Flx |
| Eyevance Pharmaceuticals LLC | $16.07 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.